VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Salmonella Enteritidis guaBA/clpP mutant vaccine
Vaccine Information
  • Vaccine Name: Salmonella Enteritidis guaBA/clpP mutant vaccine
  • Target Pathogen: Salmonella spp.
  • Target Disease: Salmonellosis
  • Product Name: CVD 1941
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • clpP gene engineering:
    • Type: Gene mutation
    • Description: This guaBA/clpP mutant is from Salmonella Enteritidis (Tennant et al., 2011).
    • Detailed Gene Information: Click Here.
  • guaA gene engineering:
    • Type: Gene mutation
    • Description: This guaBA/clpP mutant is from Salmonella Enteritidis (Tennant et al., 2011).
    • Detailed Gene Information: Click Here.
  • guaB from S. enteritidis str. P125109 gene engineering:
    • Type: Gene mutation
    • Description: This guaBA/clpP mutant is from Salmonella Enteritidis (Tennant et al., 2011).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral immunization
Host Response

Mouse Response

  • Persistence: A guaBA/clpP mutant is attenuated in mice (Tennant et al., 2011).
  • Efficacy: A guaBA/clpP mutant induces protection in mice from challenge with wild type Salmonella Enteritidis. The vaccine efficacy is 76% (Tennant et al., 2011).
  • Host IgG response
    • Description: Immune responses induced included high levels of serum IgG anti-lipopolysaccharide (LPS), with titers increasing progressively during the immunization schedule. For mice immunized with attenuated S. Enteritidis vaccine candidates, there was a trend of higher seroconversion rates after the first dose (26 days after immunization) in mice that received CVD 1941 than for those immunized with CVD 1943, which was statistically significant for anti-FliC (Tennant et al., 2011).
    • Detailed Gene Information: Click Here.
References
Tennant et al., 2011: Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, Gat O, Levine MM. Engineering and pre-clinical evaluation of attenuated non-typhoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infection and immunity. 2011; ; . [PubMed: 21807911].